Vivoryon Therapeutics N.V. · EURONEXT:VVY
Vivoryon Therapeutics — FY2024 Earnings Presentation
32 slides from Vivoryon Therapeutics's earnings presentation, Apr 29, 2025
Slide 1: FY 2024: Financial Results & Operational Update
FY 2024: Financial Results & Operational Update A year marked by positive kidney function data and progress in advancing varoglutamstat in kidney disease April 29, 2025 Vivoryon Therapeutics N.V.
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Shaping the future of Vivoryon in kidney disease: 2024/2025 YTD progress
Shaping the future of Vivoryon in kidney disease: 2024/2025 YTD progress Built Robust Body of Designed Efficient Clearly Defined Viable Focused on Securing Clinical Evidence Clinical Program Commercial Strategy Company for Future ◆ Robust data from two ◆ Planned Phase 2b ◆ Successful strategic ◆ Cas
Slide 4: Robust body of evidence for varoglutamstat in kidney supports strategic shift
Robust body of evidence generated for varoglutamstat in kidney supports strategic shift towards advancing varoglutamstat in DKD YTD Q4 Meta-analysis data support consistent effect and high response rates Q3 Data presented at ASN ◆ Responder analysis showed eGFR predominantly Kidney Week; confirmed i
Slide 5: 2024 Financial Results & Corporate Updates
2024 Financial Results & Corporate Updates Anne Döring, CFO
Slide 6: Prudent spending allowed strategic turnaround towards kidney disease while reducing cash utilization
Prudent spending allowed us to achieve strategic turnaround towards kidney disease while reducing cash utilization In €k Twelve months ended Twelve months ended Dec. 31, 2024 Dec. 31, 2023 Revenue 0 (3,620)^ Research & Development expenses (14,058) (17,637) General & Administrative expenses (6,903)
Slide 7: Cash runway extended into January 2026; SEPA with Yorkville provides flexibility
Cash runway extended into January 2026; SEPA with Yorkville provides financial flexibility beyond updated guidance Improved outlook - cash runway now into SEPA is one piece of our financial strategy January 2026* towards starting our Phase 2b DKD study ◆ Successfully managed 2024 challenges ◆ Standb
Slide 8: Strengthening a seasoned senior management team
Strengthening a seasoned senior management team Management Joining May 1, 2025 Frank Weber, MD Anne Doering, CFA Michael Schaeffer, PhD Julia Neugebauer, PhD Chief Executive Officer Chief Financial Officer Chief Business Officer Chief Operating Officer Non-executive Directors ◆ Julia Neugebauer, PhD
Slide 9: Varoglutamstat has a novel MOA with new pre-clinical evidence
Varoglutamstat has a novel MOA with new pre-clinical evidence showing potential synergistic effect with current SoC Michael Schaeffer, CBO
Slide 10: Inhibition of QPCT/L reduces kidney inflammation and fibrosis
Groundbreaking discovery: Inhibition of QPCT/L reduces kidney inflammation and fibrosis, and improves pathophysiology and kidney function improved kidney QPCT/L inhibition leads to activity modulation of Varoglutamstat inflammatory and impaired kidney fibrotic peptides QPCT/L substrate protein Kidne
Slide 11: SGLT-2 Inhibitors are now standard of care for patients with CKD
SGLT-2 Inhibitors are now standard of care for patients with CKD (KDIGO 24) KDIGO 2024 recommends SGLT2i for patients with ◆ Type 2 diabetes, CKD, and an eGFR ≥ 20 mL/min/1.73 m2 ◆ Adults with CKD eGFR ≥ 20 mL/min/1.73 m 2 with urine ACR ≥ 200 mg/g or heart failure, irrespective of level of albuminu
Slide 12: Evaluation of varoglutamstat in ADI-CKD model of CKD
Evaluation of varoglutamstat in ADI-CKD model of CKD ◆ ADI-CKD – established animal model for CKD; CKD is induced by an adenine-rich diet in rat/mice1 ◆ High doses of adenine lead to accumulation and crystallization of a metabolic product (2,8-DHA), which induces kidney inflammation - a major mechan
Slide 13: Synergistic effects of dapagliflozin plus varoglutamstat in CKD mouse model
Impressive synergistic effects of dapagliflozin plus varoglutamstat - pronounced modulation of inflammatory and fibrotic mechanisms in CKD mouse model Results pave the development path of QPCT/L inhibitors in combination with SGLT-2 inhibitors Inflammation (CD11c) ◆ Efficacy observed on top of SGLT-
Slide 14: Continuing to evolve IP strategy based on scientific evidence
Continuing to evolve IP strategy based on scientific evidence
Slide 15: Bolstering IP portfolio on multiple levels
Bolstering IP portfolio on multiple levels: Solid IP strategy spanning composition of matter and indication / dosing patents ◆ Received Notice of Allowance for new varoglutamstat composition of matter (COM) patent in the U.S. following accelerated examination process – Recent updates exclusivity exp
Slide 16: US IP strategy aims for exclusivity until at least 2044
Our IP-strategy in the US aims to generate exclusivity for varoglutamstat up until at least 2044, with potential for further extensions PTE option HCl polymorph, NoA received 2044 max. 2049 Composition of matter 2045 max. 2050 Broad, all salts, filed Medical use kidney 2045 max.2050 Broad, all salts
Slide 17: A convenient new treatment option to fill the gap in kidney diseases
A convenient new treatment option to fill the existing gap in kidney diseases Product profile demonstrates varoglutamstat has the potential to stabilize/counteract continuous decline in kidney function as single agent and in combination with SoC Single agent oral compound, in addition pre-clinical e
Slide 18: Varoglutamstat's unique and beneficial effect on kidney function
Varoglutamstat’s unique and beneficial effect on kidney function Frank Weber, CEO
Slide 19: Novel therapies are needed to address rising global kidney disease challenge
Novel therapies are needed to address the rising global health challenge of kidney disease Vivoryon’s varoglutamstat has potential to transform kidney outcomes ◆ Chronic Kidney Disease (CKD) is a rising global health problem and is set to become the fifth leading Current therapies do not halt or rev
Slide 20: Two independent randomized placebo-controlled Phase 2 studies: VIVIAD & VIVA-MIND
Vivoryon has evaluated varoglutamstat’s effect on kidney function in two independent randomized double-blind placebo-controlled Phase 2 studies Similarities and differences between VIVIAD & VIVA-MIND Parameter VIVIAD (Europe) VIVA-MIND (U.S.) Patient selection Mild AD, mean age 68 yrs Mild AD, mean
Slide 21: Beneficial kidney function effect observed in both VIVIAD and VIVA-MIND
Beneficial kidney function effect consistently observed in both VIVIAD and VIVA-MIND Two independent studies confirm statistically significant and clinically meaningful improvement in eGFR LSmean difference of eGFR between varoglutamstat 600mg BID and placebo (all patients, all visits with eGFR asse
Slide 22: Meta-analysis confirms robust treatment effect, larger in diabetes patients
VIVIAD and VIVA-MIND: Meta-analysis confirms a robust treatment effect and a larger effect size in diabetes versus non-diabetes patients Difference of change from baseline between varoglutamstat (v) and placebo (p) of eGFR (MDRD) Up-titration ∆ = 1.8 mL/min/1.73m2 ∆ = 1.5 mL/min/1.73m2 p=0.55 p=0.17
Slide 23: Change in eGFR over time; pooled data, all subjects
Change in eGFR over time; pooled data from VIVIAD and VIVA-MIND (MMRM); All subjects; 600mg BID varoglutamstat Varoglutamstat ◆ Clear and consistent separation after 24 weeks ◆ Effect stable and maintained above baseline for 2 years ◆ Placebo patients decline mildly BID eGFR: estimated glomerular fi
Slide 24: Change in eGFR over time; diabetes subgroup
Change in eGFR over time; pooled data from VIVIAD and VIVA-MIND (MMRM); Diabetes subgroup; 600mg BID varoglutamstat Varoglutamstat ◆ Clear and consistent separation after 24 weeks ◆ Large and stable effect maintained above baseline for 2 years ◆ Larger treatment effect in diabetes patients* ◆ Placeb
Slide 25: Responder analysis: kidney function improved or stabilized in treated patients
Responder analysis: kidney function predominantly improved or stabilized in varoglutamstat treated patients compared to a decline in the placebo group Diabetes patients pooled VIVIAD & VIVA-MIND 100% % patients with eGFR response of improving, stable 90% 22% Classification of eGFR response 80% 38% (
Slide 26: Varoglutamstat was well tolerated in VIVIAD & VIVA-MIND
Varoglutamstat was well tolerated in VIVIAD & VIVA-MIND Pooled safety analysis; 600mg varoglutamstat dose All patients randomized to 600mg varoglutamstat BID and placebo Extensive safety package (# / duration) 90 Pharmacology / Phase 1 80 ◆ Phase 1 study: large trial with 205 % of patients with an e
Slide 27: Phase 2b study design in patients with T2DM and CKD stages 3b+
Robust evidence supports move into Phase 2b study: double-blind placebo- controlled study in patients with T2DM and CKD stages 3b+ on top of SoC 1 End of Phase 2b Safety follow up Randomization (up to 6 weeks) PRIMARY (1:1, N = 90) Placebo Screening ENDPOINT (eGFR change Varoglutamstat 600 mg QD fro
Slide 28: Conclusions
Conclusions
Slide 29: Vivoryon product strategy
Vivoryon product strategy Create value and robust evidence for QPCT/L inhibitors in improving kidney function in patients with CKD 2024 2025 and beyond ◆ Deliver two high quality Phase 2 studies: VIVIAD ◆ Ensure the commercial viability of varoglutamstat and VIVA-MIND with novel composition of matte
Slide 30: The future of Vivoryon: Improving kidney outcomes
The future of Vivoryon: Improving kidney outcomes ◆ Novel MoA ◆ Robust evidence of a long-term effect Strong scientific ◆ Excellent safety package foundation ◆ Strong benefit on top of SoC ◆ QPCT/L inhibitor pipeline ◆ Large population with high unmet medical need Clearly defined ◆ Unique product pr
Slide 31: Q&A
Q&A
Slide 32: Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany [email protected] +49 (0)345 555 99 00 www.vivoryon.com